Core Insights - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation adjustments, with Rui Sheng's valuation dropping from 1.7 billion RMB to 974 million RMB due to performance declines [7][18] - The presence of a company that was not yet established as a major client of Rui Sheng raises questions about the accuracy of financial disclosures [9][11] - The investigation revealed inconsistencies in client relationships and potential issues with financial reporting practices [20][21] Group 1 - Haili Biological acquired 55% of Rui Sheng Biological for 935 million RMB, resulting in a valuation increase of 952% at the time of acquisition [7] - Rui Sheng Biological's valuation was subsequently revised downwards due to declining performance, with a projected valuation of 974 million RMB by June 2025 [7][18] - The company claims to be a leading player in the market for natural calcined bone repair materials, particularly in dental applications [7] Group 2 - Wuhan He Mu Medical Technology, a client listed by Rui Sheng, was found to have been established only in April 2023, raising questions about its status as a major client [10][11] - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [11][18] - The investigation into client relationships revealed that actual business dealings may have been misrepresented, with claims of shared operations between different entities [13][15] Group 3 - The performance of Rui Sheng Biological has been adversely affected by increased competition and price wars, leading to a significant drop in revenue and profit margins [42][43] - The company reported a revenue of 26.77 million RMB and a net profit of 9.29 million RMB in Q3 2025, indicating a substantial decline compared to previous quarters [42] - Haili Biological plans to expand its operations by acquiring stakes in dental chain companies, which is expected to positively impact its financial performance in 2026 [43][44]

Core Viewpoint - The acquisition price of 55% stake in Ruisheng Bio by Haili Bio has been reduced from 935 million yuan to 536 million yuan due to the decline in Ruisheng Bio's operating performance, which helps to lower investment costs and control risks for the company and its shareholders [1][3] Group 1: Acquisition Details - Haili Bio announced the adjustment of the acquisition price for Ruisheng Bio's 55% stake from 935 million yuan to 536 million yuan, with corresponding adjustments to performance commitments for 2025 and 2026 [1] - The transaction was completed in October last year, and Ruisheng Bio has met its net profit commitment for 2024 [1] - The adjustment will result in a return of the price difference of 399 million yuan from the counterparty and is expected to reduce the goodwill formed during the acquisition [1] Group 2: Industry Context - Ruisheng Bio operates in the oral regenerative medicine sector, with its core product being natural calcined bone repair materials [2] - The industry is experiencing a "price war," with Ruisheng Bio's oral product line prices dropping nearly 30% year-on-year in Q1 2025 and a further 40% decline in Q2 [2] - Tax incentives previously applicable to Ruisheng Bio have been tightened, changing from a simplified VAT rate of 3% to a general rate of 13% [2] Group 3: Company Performance - Despite the challenges, Ruisheng Bio has increased its market share of bone powder and bone membrane products by approximately 6% to 7% due to increased shipment volumes from a new facility [2] - The company is awaiting acceptance of registration applications for two products, bone repair materials and natural bone repair materials [2] - Ruisheng Bio maintains a high gross margin while enhancing services, expanding sales to public hospitals, and optimizing internal costs [2][3]